February 16, 2023

Dr. Mihael Polymeropoulos President and Chief Executive Officer Vanda Pharmaceuticals Inc. 2200 Pennsylvania Avenue NW, Suite 300E Washington, DC 20037

Pharmaceuticals Inc.

Re: Vanda

Statement on Form S-3

Registration

Statement on Form 5

Filed February 9,

2023

File No. 333-269654

Dear Dr. Mihael Polymeropoulos:

This is to advise you that we have not reviewed and will not review your registration statement.

 $\,$ Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you

that the company and its management are responsible for the accuracy and adequacy of their $\,$

disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Cindy

Polynice at 202-551-8707 with any questions.

Sincerely,

Division of Corporation Finance

Office of Life Sciences

cc: Gregg A. Griner, Esq.